Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Indivior    INDV   GB00BRS65X63

INDIVIOR

(INDV)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Indivior : loses U.S. district court battle, copycat launches imminent

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/12/2019 | 02:29am EST

(Reuters) - Generic competitors to British drugmaker Indivior Plc's blockbuster opioid addiction treatment are on course to launch sales next week after the firm's attempt to stay a U.S. District court judgement was rejected.

The company said on Tuesday it would file a repeat motion to the Supreme Court, after having said last week that it faces rapid losses in market share "in the immediate future" to generic versions of Suboxone.

Earlier this month, a mandate by the U.S. Court of Appeals for the Federal Circuit opened the gates to rivals including India's Dr. Reddy's.

(Reporting by Pushkala Aripaka in Bengaluru; Editing by Arun Koyyur)

Stocks mentioned in the article
ChangeLast1st jan.
DR. REDDY'S LABORATORIES LTD -3.90% 2563.35 End-of-day quote.-2.03%
INDIVIOR 5.44% 113.35 Delayed Quote.0.89%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on INDIVIOR
02/15INDIVIOR : boosts profits, but warns of rising competition in America
AQ
02/14LONDON STOCK EXCHANGE : FTSE 100 squeezes out gains; ConvaTec drags midcaps
RE
02/14INDIVIOR : Costs cuts help Indivior post 2018 profit jump
RE
02/12INDIVIOR : Court Denies Emergency Motion to Block Dr. Reddy's Generic Medicine L..
DJ
02/12INDIVIOR : loses U.S. district court battle, copycat launches imminent
RE
02/11INDIVIOR PLC : annual earnings release
02/05FTSE 100 at near-three-month high, BP shines on strong 2018
RE
02/05INDIVIOR : U.S. Court Denies Indivior Rehearing in Dr. Reddy's Case
DJ
02/05INDIVIOR : braces for market share slide after U.S. court defeat
RE
02/05INDIVIOR : sells rights to addiction drug for $122m
AQ
More news
Financials ($)
Sales 2019 562 M
EBIT 2019 37,1 M
Net income 2019 32,4 M
Finance 2019 115 M
Yield 2019 -
P/E ratio 2019 -
P/E ratio 2020 13,91
EV / Sales 2019 1,68x
EV / Sales 2020 1,54x
Capitalization 1 058 M
Chart INDIVIOR
Duration : Period :
Indivior Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INDIVIOR
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 2,76 $
Spread / Average Target 89%
EPS Revisions
Managers
NameTitle
Shaun Thaxter Chief Executive Officer & Executive Director
Howard H. Pien Chairman
Mark Crossley Chief Financial Officer & Executive Director
Christian Heidbreder Chief Scientific Officer
Ingo Elfering Chief Information Officer
Sector and Competitors
1st jan.Capitalization (M$)
INDIVIOR0.89%1 058
ABBVIE-12.30%121 616
MERCK KGAA7.71%14 147
KYOWA HAKKO KIRIN CO LTD5.23%11 129
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD13.36%8 757
JAZZ PHARMACEUTICALS PLC1.10%7 596